LetterLetter
Dr. Degar et al reply
Barbara A. Degar, Olha Halyabar, Melissa M. Hazen and Lauren A. Henderson
The Journal of Rheumatology November 2022, jrheum.221078; DOI: https://doi.org/10.3899/jrheum.221078
Barbara A. Degar
Department of Pediatric Oncology, Dana Farber Cancer Institute; Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA. This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, K08 AR073339-01 (LAH), and the Boston Children's Hospital Department of Medicine Evidence Based Guideline Program (LAH and MMH). LAH had received salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.A. Henderson, 1 Blackfan Circle, Karp Family Research Building, 10th Floor, Boston, MA 02115, USA. Email: Lauren.Henderson@childrens.harvard.edu.
Olha Halyabar
Department of Pediatric Oncology, Dana Farber Cancer Institute; Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA. This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, K08 AR073339-01 (LAH), and the Boston Children's Hospital Department of Medicine Evidence Based Guideline Program (LAH and MMH). LAH had received salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.A. Henderson, 1 Blackfan Circle, Karp Family Research Building, 10th Floor, Boston, MA 02115, USA. Email: Lauren.Henderson@childrens.harvard.edu.
Melissa M. Hazen
Department of Pediatric Oncology, Dana Farber Cancer Institute; Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA. This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, K08 AR073339-01 (LAH), and the Boston Children's Hospital Department of Medicine Evidence Based Guideline Program (LAH and MMH). LAH had received salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.A. Henderson, 1 Blackfan Circle, Karp Family Research Building, 10th Floor, Boston, MA 02115, USA. Email: Lauren.Henderson@childrens.harvard.edu.
Lauren A. Henderson
Department of Pediatric Oncology, Dana Farber Cancer Institute; Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA. This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, K08 AR073339-01 (LAH), and the Boston Children's Hospital Department of Medicine Evidence Based Guideline Program (LAH and MMH). LAH had received salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.A. Henderson, 1 Blackfan Circle, Karp Family Research Building, 10th Floor, Boston, MA 02115, USA. Email: Lauren.Henderson@childrens.harvard.edu.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Dr. Degar et al reply
Barbara A. Degar, Olha Halyabar, Melissa M. Hazen, Lauren A. Henderson
The Journal of Rheumatology Nov 2022, jrheum.221078; DOI: 10.3899/jrheum.221078